FFTYCapForce IBD 50 ETF
Seeks to track the performance of the IBD 50 Index (the Index).
By Capital-FORCE ETF · Launched 2015
Annual Cost
0.80%
#4,189 of 5,562 · expensive
Fund Size
$90M
#3,047 of 5,562 · mid-size
Return (1Y)Goal
+42.5%
Track Record
11 years
#1,285 of 5,562 · established
Performance
Total-return NAV · USDGrowth of $10,000
$13,783+37.8%
Total-return NAV, USD. Net of fund fees, before tax.
Classification
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Factor
Momentum
Index tracked
IBD 50 Index
What it actually holds
By weightConcentration
Top 10 holdings = 51.6% of fundmoderately concentrated
Mount Vernon Liquid Assets Portfolio, LLC
19.2%
Mirum Pharmaceuticals Inc
4.1%
Micron Technology Inc
3.9%
AnaptysBio Inc
3.7%
Comfort Systems USA Inc
3.6%
FTAI Aviation Ltd
3.5%
IAMGOLD Corp
3.5%
PACS Group Inc
3.4%
Rocket Lab Corp
3.3%
Celestica Inc
3.3%
Asset allocation
Stocks
99.8%
Cash
0.2%
Other
0.0%
By sector
Technology
39.4%
Industrials
23.1%
Healthcare
12.8%
Energy
7.3%
Financial Services
6.7%
Basic Materials
2.9%
Communication
2.8%
Consumer Defensive
2.8%
Other
2.3%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
35.7%High
Year-on-year price swings
Max drawdown
-59.5%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.66Decent risk-adjusted returns
Sortino (3Y)
0.91Moderate downside risk
Where to buy
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks to track the performance of the IBD 50 Index (the Index).
- Strategy
- Invests primarily in securities that comprise the IBD 50 Index, aiming for a correlation of 0.95 or better with the Index's performance. The Fund will concentrate its investments in the same industries as the Index, which focuses on top growth stocks. The Index is rebalanced weekly, and the Fund will have a higher portfolio turnover rate than similar funds due to this frequent reconstitution.
- Inception date
- April 8, 2015
- Fund family
- Capital-FORCE ETF
Similar ETFs
Closest matches by profileWhat's next?
You've reviewed FFTY. Save it to your watchlist to track it alongside the other funds you're weighing.
Data updated on 2026-06-19